Topic · Hepatitis C virus research
Most cited papers in Hepatitis C virus research
What are the most cited papers in Hepatitis C virus research?
The most cited paper in Hepatitis C virus research is "Hepatocellular carcinoma" (Josep Maria Llovet, Robin Kate Kelley, Augusto García Villanueva et al., 2021), with 6,733 citations. Next come "Peginterferon Alfa-2a plus Ribavirin for Chronic Hepatitis C Virus Infection" (6,410) and "Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial" (6,056).
Showing 50 of 100 papers. Every paper with more than 1,416 citations is listed.
| # | Paper | ||
|---|---|---|---|
| 1 | Hepatocellular carcinoma Josep Maria Llovet, Robin Kate Kelley, Augusto García Villanueva et al. · Nature Reviews Disease Primers | 21 Jan 2021 | 6,733 |
| 2 | Peginterferon Alfa-2a plus Ribavirin for Chronic Hepatitis C Virus Infection Michael Fried, Mitchell L. Shiffman, K. Rajender Reddy et al. · New England Journal of Medicine | 25 Sep 2002 | 6,410 |
| 3 | Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial Michael Peter Manns, John G. McHutchison, Stuart C. Gordon et al. · The Lancet | Sep 2001 | 6,056 |
| 4 | EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection Pietro Lampertico, Kosh Agarwal, Thomas Berg et al. · Journal of Hepatology | 18 Apr 2017 | 5,528 |
| 5 | Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection†‡ Richard K. Sterling, Eduardo Lissen, Nathan Clumeck et al. · Hepatology | 25 May 2006 | 4,995 |
| 6 | The HCV Life Cycle: In vitro Tissue Culture Systems and Therapeutic Targets Gisa Gerold, Thomas Pietschmann · Digestive Diseases | 2014 | 4,864 |
| 7 | A Simple Noninvasive Index Can Predict Both Significant Fibrosis and Cirrhosis in Patients With Chronic Hepatitis C Chun‐Tao Wai, Joel K. Greenson, Robert J. Fontana et al. · Hepatology | 25 Jul 2003 | 4,422 |
| 8 | Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance Norah A. Terrault, Anna S. Lok, Brian J. McMahon et al. · Hepatology | 5 Feb 2018 | 4,390 |
| 9 | An Algorithm for the Grading of Activity in Chronic Hepatitis C Pierre Bédossa, Thierry Poynard · Hepatology | Aug 1996 | 4,058 |
| 10 | Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance Dongliang Ge, Jacques Fellay, Alexander J. V. Thompson et al. · Nature | 16 Aug 2009 | 3,535 |
| 11 | Interferon Alfa-2b Alone or in Combination with Ribavirin as Initial Treatment for Chronic Hepatitis C John G. McHutchison, Stuart C. Gordon, Eugene R. Schiff et al. · New England Journal of Medicine | 19 Nov 1998 | 3,509 |
| 12 | Epidemiology of Viral Hepatitis and Hepatocellular Carcinoma Hashem B. El‐Serag · Gastroenterology | 24 Apr 2012 | 3,459 |
| 13 | Effect of pegylation on pharmaceuticals J. Milton Harris, Robert B. Chess · Nature Reviews Drug Discovery | 28 Feb 2003 | 3,437 |
| 14 | An Assay for Circulating Antibodies to a Major Etiologic Virus of Human Non-A, Non-B Hepatitis George C. Kuo, Q L Choo, Harrison Alter et al. · Science | 21 Apr 1989 | 3,383 |
| 15 | Risk of Hepatocellular Carcinoma Across a Biological Gradient of Serum Hepatitis B Virus DNA Level Chien‐Jen Chen · JAMA | 3 Jan 2006 | 3,164 |
| 16 | Chronic hepatitis B Anna S. Lok, Brian J. McMahon · Hepatology | 26 Jan 2007 | 3,096 |
| 17 | Natural history of liver fibrosis progression in patients with chronic hepatitis C Thierry Poynard, Pierre Bédossa, Pierre Opolon · The Lancet | Mar 1997 | 3,042 |
| 18 | The Prevalence of Hepatitis C Virus Infection in the United States, 1988 through 1994 Miriam J. Alter, Deanna Kruszon-Moran, Omana V. Nainan et al. · New England Journal of Medicine | 19 Aug 1999 | 3,028 |
| 19 | Hepatitis C Virus Infection Georg Michael Lauer, Bruce D. Walker · New England Journal of Medicine | 5 Jul 2001 | 2,985 |
| 20 | Diagnosis, management, and treatment of hepatitis C: An update # † ‡ Marc G. Ghany, Doris B. Strader, David L. Thomas et al. · Hepatology | 2 Dec 2008 | 2,985 |
| 21 | International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis Fernando Villar Álvarez et al. · Journal of Hepatology | Nov 1999 | 2,928 |
| 22 | HEPATOCELLULAR CARCINOMA AND HEPATITIS B VIRUS R. Palmer Beasley, Chia‐Chin Lin, Lu‐Yu Hwang et al. · The Lancet | Nov 1981 | 2,879 |
| 23 | Type I interferons in infectious disease Finlay W. McNab, Katrin D. Mayer-Barber, Alan Sher et al. · Nature reviews. Immunology | 23 Jan 2015 | 2,863 |
| 24 | Chronic hepatitis B: Update 2009 # Anna S. Lok, Brian J. McMahon · Hepatology | 28 Jul 2009 | 2,851 |
| 25 | Peginterferon-α2a and Ribavirin Combination Therapy in Chronic Hepatitis C Stephanos J. Hadziyannis, Hoel Sette, Timothy R. Morgan et al. · Annals of Internal Medicine | 2 Mar 2004 | 2,842 |
| 26 | Replication of Subgenomic Hepatitis C Virus RNAs in a Hepatoma Cell Line Volker Lohmann, Frank Körner, Jan Oliver Koch et al. · Science | 2 Jul 1999 | 2,814 |
| 27 | Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013 Aparna Schweitzer, Johannes Horn, Rafael Mikolajczyk et al. · The Lancet | 28 Jul 2015 | 2,802 |
| 28 | Global epidemiology of hepatitis C virus infection Colin W. Shepard, Lyn Finelli, Miriam J. Alter · The Lancet Infectious Diseases | 25 Aug 2005 | 2,769 |
| 29 | Production of infectious hepatitis C virus in tissue culture from a cloned viral genome Takaji Wakita, Thomas Pietschmann, Takanobu Kato et al. · Nature Medicine | 12 Jun 2005 | 2,753 |
| 30 | Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures Daniel Lavanchy · Journal of Viral Hepatitis | 20 Feb 2004 | 2,663 |
| 31 | Hepatocellular carcinoma in cirrhosis: Incidence and risk factors Giovanna Fattovich, Tommaso Stroffolini, I. Zagni et al. · Gastroenterology | Nov 2004 | 2,615 |
| 32 | An inventory for assessing different kinds of hostility. Arnold H. Buss, Ann Durkee · Journal of Consulting Psychology | 1957 | 2,615 |
| 33 | Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update Shiv Kumar Sarin et al. · Hepatology International | 13 Nov 2015 | 2,603 |
| 34 | The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide Joseph F. Perz, Gregory L. Armstrong, Leigh A. Farrington et al. · Journal of Hepatology | 24 Jun 2006 | 2,597 |
| 35 | Hepatitis B Virus Infection William M. Lee · New England Journal of Medicine | 11 Dec 1997 | 2,588 |
| 36 | A diverse range of gene products are effectors of the type I interferon antiviral response John W. Schoggins, Sam J. Wilson, Maryline Panis et al. · Nature | 8 Apr 2011 | 2,545 |
| 37 | Global epidemiology of hepatitis C virus infection: New estimates of age-specific antibody to HCV seroprevalence Khayriyyah Mohd Hanafiah, Justina L. Groeger, Abraham D. Flaxman et al. · Hepatology | 21 Nov 2012 | 2,532 |
| 38 | Boceprevir for Untreated Chronic HCV Genotype 1 Infection Fred F Poordad, Jonathan McCone, Bruce R. Bacon et al. · New England Journal of Medicine | 30 Mar 2011 | 2,519 |
| 39 | Primary liver cancer: Worldwide incidence and trends Francesc Xavier Bosch, Josepa Ribes, Mireia Díaz et al. · Gastroenterology | Nov 2004 | 2,507 |
| 40 | The Immune Epitope Database (IEDB): 2018 update Randi Vita, Swapnil Mahajan, James A. Overton et al. · Nucleic Acids Research | 11 Oct 2018 | 2,400 |
| 41 | Telaprevir for Previously Untreated Chronic Hepatitis C Virus Infection Ira M. Jacobson et al. · New England Journal of Medicine | 22 Jun 2011 | 2,394 |
| 42 | Hepatitis B Virus Infection — Natural History and Clinical Consequences Don Ganem, Alfred M. Prince · New England Journal of Medicine | 10 Mar 2004 | 2,384 |
| 43 | Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus Thierry Poynard, Patrick Marcellin, Samuel S. Lee et al. · The Lancet | Oct 1998 | 2,335 |
| 44 | Fibrosis stage is the strongest predictor for disease‐specific mortality in NAFLD after up to 33 years of follow‐up Mattias Ekstedt, Hannes Hagström, Patrik Nasr et al. · Hepatology | 14 Aug 2014 | 2,302 |
| 45 | Lamivudine for Patients with Chronic Hepatitis B and Advanced Liver Disease Yun‐Fan Liaw, Joseph J.�Y. Sung, Wan Cheng Chow et al. · New England Journal of Medicine | 6 Oct 2004 | 2,281 |
| 46 | Results of a Prospective Study of Acute Liver Failure at 17 Tertiary Care Centers in the United States George Ostapowicz, Robert J. Fontana, Frank Vinholt Schiødt et al. · Annals of Internal Medicine | 17 Dec 2002 | 2,250 |
| 47 | Complete Replication of Hepatitis C Virus in Cell Culture Brett D. Lindenbach, Matthew J. Evans, Andrew J. Syder et al. · Science | 9 Jun 2005 | 2,244 |
| 48 | Sampling Variability of Liver Fibrosis in Chronic Hepatitis C Pierre Bédossa, Delphine Dargère, Valérie Paradis · Hepatology | 25 Nov 2003 | 2,234 |
| 49 | Treatment of HCV Infection by Targeting MicroRNA Harry L.A. Janssen, Hendrik W. Reesink, Eric Lawitz et al. · New England Journal of Medicine | 27 Mar 2013 | 2,233 |
| 50 | Genetic variation in IL28B and spontaneous clearance of hepatitis C virus David L. Thomas, Chloe L. Thio, Maureen P. Martin et al. · Nature | 16 Sep 2009 | 2,165 |
Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for a field when OpenAlex files it under one of the field's topics; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.